01 Growing Shift Toward Multi-Platform and Advanced Robotic Surgery Systems Hospitals are increasingly moving beyond single-platform robotic programs as newer systems enter clinical use and gain regulatory clearance. This broadening technology base gives healthcare providers more options when selecting systems for different procedures and surgical specialties. Greater competition can also encourage improvements in workflow, equipment design, service models, and instrument availability. December 2025 – The U.S. FDA cleared Medtronic’s Hugo robotic-assisted surgery system for urologic procedures and CMR Surgical’s Versius Plus system for general surgical applications.
01 Growing Robotic Procedure Volumes Increase Demand for Surgical Systems and Instruments Increasing use of robotic assistance across general surgery, urology, gynecology, and other procedures is creating direct demand for surgical systems, instruments, accessories, and services. Hospitals can improve utilization of expensive robotic platforms when more surgeons and specialties perform procedures on the same installed equipment. In January 2026, Intuitive reported that approximately 3.15 million da Vinci procedures were performed worldwide in 2025, around 18% more than approximately 2.68 million procedures in 2024.
01 High Capital and Recurring Costs Restrict Adoption Among Budget-Constrained Hospitals High equipment and operating costs continue to restrict robotic surgery adoption, particularly among smaller hospitals and facilities with limited procedure volumes. Purchasing a robotic system requires considerable capital, while hospitals must also budget for instruments, accessories, maintenance, servicing, staff training, and operating-room requirements. Many instruments have limited usable lives and require replacement, creating recurring expenses after installation. Hospitals therefore need sufficient procedure volumes to spread these costs across more operations and justify investment. Facilities performing fewer suitable surgeries may find conventional laparoscopic equipment more economical. Although leasing and usage-based arrangements can reduce initial spending, the overall financial commitment can still delay purchasing decisions and limit penetration in cost-sensitive healthcare systems.In March 2025, Intuitive reported that da Vinci systems generally sold for about USD 0.7 million to USD 3.1 million, while annual service contracts typically ranged from USD 100,000 to USD 225,000.
01 Public Healthcare Expansion Creates New Demand for Robot-Assisted Surgery Expansion of robotic surgery within public healthcare systems creates an opportunity to move the technology from selected specialist centers into routine surgical care. Government-backed programs can support wider deployment by coordinating equipment procurement, surgeon training, clinical guidelines, operating-room planning, and patient access across hospital networks. Greater adoption can generate demand not only for robotic systems but also for instruments, maintenance, training, and digital support services. Wider public-sector adoption may also expose more patients and clinicians to robotic procedures, creating a larger long-term installed base and supporting broader commercialization across healthcare systems.In June 2025, NHS England projected that robot-assisted operations could increase from around 70,000 in 2023/24 to 500,000 annually by 2035, with robots supporting nine in ten keyhole surgeries.
01 System Reliability and Software Issues Increase Safety and Quality-Control Requirements Maintaining reliable performance is a major challenge as robotic surgical systems become more dependent on software, sensors, displays, mechanical arms, cameras, and interconnected components. A malfunction during surgery can interrupt clinical workflows and may require troubleshooting, equipment replacement, or conversion to another surgical approach. Hospitals must also train surgical teams to recognize equipment problems and respond appropriately to technical alerts. Increasing technological complexity can make these responsibilities more demanding. Product recalls or software problems may additionally affect hospital confidence, making reliability, quality control, and responsive technical support important requirements for continued market expansion.In February 2026, the U.S. FDA posted a Class II recall involving da Vinci 5 systems after a software-related error could cause user-interface crashes and loss of interaction at an affected display node.
September 2025 Johnson & Johnson expanded its surgical robotics portfolio through its Ottava™ robotic surgical system development program, advancing next-generation robotic-assisted surgery technologies.
July 2025 Stryker expanded its robotic surgery capabilities by advancing its Mako™ robotic-arm assisted surgery platform, supporting orthopedic procedures with improved surgical planning and precision technologies.
June 2025 Medtronic expanded its robotic-assisted surgery portfolio by advancing the Hugo™ robotic-assisted surgery system and strengthening surgical technology development for minimally invasive procedures.
May 2025 Intuitive Surgical expanded its robotic surgery portfolio by advancing the da Vinci® surgical system ecosystem with new digital capabilities, training initiatives, and procedural enhancements to support minimally invasive surgery adoption.